Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients

Melanoma Clinical Trial

— THERAVAC  

Official title:

Phase I/II Study of Therapeutic Vaccination With Escalating Doses of Theravac®, a Proteinic Vector Targeting Dendritic Cells Coupled to a Melanoma Antigen, in Patients With Advanced Metastatic Melanoma.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01331915
• Other study ID #: LUC 09-003
• Secondary ID: 2009-014651-77
• Status: Recruiting
• Phase: Phase 1/Phase 2
• First received: January 20, 2011
• Last updated: October 8, 2012
• Start date: September 2010

Study information

• Verified date: October 2012
• Source: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
• Contact: Jean-François Baurain, MD, PhD
• Phone: 0032 2 764 54 71
• Email: jean-francois.baurain[@]uclouvain.be
• Is FDA regulated: No
• Health authority: Belgium: Federal Agency for Medicinal Products and Health Products
• Study type: Interventional

Clinical Trial Summary

In this phase I study, the investigators want to vaccine with THERAVAC® (an inactivated toxin coupled to melanoma antigen) some patients with advanced metastatic melanoma disease.

The primary objective is to analyze the safety of the inreasing doses of vaccine.

The secondary objective is to document whether this vaccine can induce tumor regression in immunized patients.

Description:

There are three treatment cohorts and the inclusion of patients in governed by the dose-limiting toxicities in the previous cohort.

• the first three patients will receive a dose of 50 µg of Theravac®

• second cohort of three patients will receive a dose of 150 µg Theravac®

• the third cohort of three patients will receive a dose of 250 µg Theravac® and eventually a total of 14 patients will complete the step with the highest dose.

All the patients will receive four immunizations every three weeks in two intradermal sites and in two subcutaneous sites.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 23
• Est. primary completion date: October 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically proven cutaneous, uveal or mucosal melanoma.

2. Melanoma must be metastatic. The origin of the primary could be cutaneous, uveal or mucosal and any metastatic stage is accepted, except if brain or leptomeningeal localizations are present, or if plasma LDH are elevated more than 1.5 normal upper values (see also below).

3. HLA-A2 positive.

4. The melanoma must express the tyrosinase gene (positive RT-PCR on a frozen pre-immune tumor sample) (see Appendix B).

5. At least one measurable or non-measurable tumor lesion (see Section 8.1).

6. Expected survival of at least 3 months.

7. Karnofsky performance scale =70 or WHO performance status of 0 or 1 (see Appendix C).

8. Vital laboratory parameters should be within normal range, except for the following laboratory parameters, which must be within the ranges specified:

Lab Parameter Range Hemoglobin = 10 g/dl or = 6,25 mmol/l Granulocytes = 1,500/µl Lymphocytes = 700/µl Platelets = 100,000/µl Serum creatinin = 2.0 mg/dl or = 177 µmol/l Serum bilirubin = 2.0 mg/dl or = 34.2 µmol/l ASAT and ALAT = 2 x the normal upper limits LDH = 1.5 x the normal upper limit.

9. Viral serology:

• HIV (human immunodeficiency virus): negative antibodies.

• HBV (hepatitis B virus): negative antigens; antibodies may be positive.

• HCV (hepatitis C virus): negative antibodies.

10. Age = 18 years

11. Able and willing to give valid written informed consent

Exclusion Criteria:

1. Previous treatment with more than one regimen of systemic chemotherapy, combined or not with non-specific immunotherapy such as interferon alpha or interleukins. Chemoimmunotherapy or radiotherapy must be stopped within the preceding 4 weeks (6 weeks for nitrosoureas and mitomycin C).

2. Previous treatment with a vaccine known or likely to contain the Tyrosinase.A2 epitope YMDGTMSQV.

3. Clinically significant heart disease (NYHA Class III or IV) i.e. NYHA class 3 congestive heart failure; myocardial infarction within the past six months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias.

4. Active immunodeficiency or autoimmune disease. Vitiligo is not an exclusion criterion.

5. Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study.

6. Other malignancy within 3 years prior to entry into the study, except for treated non-melanoma skin cancer and cervical carcinoma in situ.

7. Allergy to kanamycin (used in the preparation of the recombinant protein) or to any other aminoglycoside antibiotic.

8. Lack of availability for immunological and clinical follow-up assessments.

9. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.

10. Pregnancy or breastfeeding.

11. Women of childbearing potential: Refusal or inability to use effective means of contraception.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Melanoma

Intervention

Biological:
• Theravac
Three groups with three doses (50 - 150 - 250 mcg), four times every three weeks. Injection: intradermally and subcutaneously.

Locations

Country	Name	City	State
Belgium	Cliniques universitaires Saint-Luc, Centre du Cancer	Brussels

Sponsors (2)

Lead Sponsor	Collaborator
Cliniques universitaires Saint-Luc- Université Catholique de Louvain	Institut Pasteur

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To analyze the safety and toxicity of increasing doses of Theravac® in patients with advanced metastatic melanoma	The toxicity will be assess after the treatment (3 months) for the first three patients of each group.	the first 3 months of treatment	Yes
Primary	To determine whether these immunizations result in a detectable immune response	PBMC will be obtained from the buffy-coat of 500 ml of venous blood or from 100 ml of venous blood collected before and after immunization.	Up to 24 weeks	No
Secondary	To document whether this vaccine can induce tumor regression in immunized patients.	The NEW RECIST criteria when applicable. For patients with only non-measurable lesion(s) at study entry, tumor response will be assessed descriptively.	at week 12	No